Immunotherapy Drugs Market is projected to reach USD 274.6 billion by 2025 from USD 163.0 billion in 2020, at a CAGR of 11.0% during the forecast period. The growth of this market is majorly attributed to the increasing adoption of immunotherapy drugs over conventional treatment regimens, the rising prevalence of cancer and autoimmune infectious diseases, increasing demand for monoclonal antibodies and biosimilars, and fast track approvals from regulatory bodies.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137717755
Browse in-depth TOC on "Immunotherapy Drugs Market”
114 – Tables
34 – Figures
176 – Pages
Key Market Players
The major players in the global immunotherapy drugs market are F. Hoffmann-La Roche Ltd. (UK), Pfizer Inc. (US), Merck Co (US), Novartis International AG (UK), Johnson Johnson (US), Sanofi (France), GlaxoSmithKline Plc (UK), Amgen Inc. (US), AbbVie Inc. (US), Boehringer Ingelheim (Germany), AstraZeneca (UK), and Immatics Biotechnologies (Germany), BioNTech SE, Genmab, Gilead Sciences, NBE Therapeutics, Teva Pharmaceuticals, Bayer, and Bristol-Myers Squibb.
The monoclonal antibodies segment accounted for the largest share of the immunotherapy drugs market, by type
Based on type, the global market is segmented into monoclonal antibodies, checkpoint inhibitors, interferons interleukins, and other immunotherapies. The monoclonal antibodies segment accounted for the largest share of the global market in 2019. This large share can be attributed to their high specificity and fewer side-effects, increasing focus on personalized medicines, initiatives by industry players, and the rising target disease incidence and patient pool.
Enquiry Before Buying this Report:
https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=137717755
By therapeutic area, cancer accounted for the largest market share
On the basis of therapeutic area, this market is segmented into cancer, autoimmune inflammatory diseases, infectious diseases, and other therapeutic areas. Cancer accounted for the largest share of the global immunotherapy drugs market, by therapeutic area, in 2019. The large share of this segment can be attributed to the growing prevalence of cancer, rising research activity in this area, and reimbursement coverage for immunotherapies for oncology.
By end user, hospitals to witness the highest growth during the forecast period
On the basis of end users, the global immunotherapy drugs market is broadly segmented into hospitals, clinics, and other end users. Hospitals accounted for the largest share of the global market in 2019. This segment is also estimated to grow at the highest CAGR of 12.1% over the forecast period. The large share of this segment can be attributed to the rising spending by hospitals for immunotherapies and the demand for advanced treatments currently only provided by hospitals.
Recent Developments:
- In 2019, Novartis International AG inaugurated a manufacturing facility for cell and gene therapies in Stein, Switzerland
- In 2019, Amgen launched MVASI (bevacizumab-awwb) and KANJINTI (trastuzumab-anns) in the US
- In 2019, Gilead Sciences, Inc. and Humanigen, Inc. (US) collaborated to jointly conduct a study of lenzilumab with YESCARTA in patients with relapsed or refractory diffuse large B-cell lymphoma
North America dominates the immunotherapy drugs market during the forecast period.
In 2019, North America accounted for the largest share of the immunotherapy drugs market, followed by Europe. The increasing prevalence of cancer, rising demand for quality diagnostics, the introduction of favorable reimbursement policies, and the implementation of favorable initiatives are some major factors driving the growth of the immunotherapy market in North America. However, the Asia Pacific region is expected to grow at the highest rate during the forecast period, owing to factors such as aggressive investments by key market players, increased government spending on healthcare, and rising disposable income of the population.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=137717755
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their pain points around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 Micro Quadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/immunotherapy-drug.asp
Related Report:
